BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Celosia Therapeutics Initiates Phase 1b Trial Of CTx1000 Targeting TDP 43 In ALS

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...

March 25, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

March 25, 2026 | News

Kelun Biotech Reports Strong 2025 Performance With Expanding ADC Pipeline And Commercial Momentum

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase...

March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

Eurofins Biomnis Develops LC MS MS Method For Detecting Cereulide Toxin In Human Stool Samples

Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announ...

March 12, 2026 | News

Ascletis Reports Positive Phase II Results For Monthly ASC30 Injection In Obesity Treatment

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of ...

March 11, 2026 | News

Lynk Pharmaceuticals Reports Positive Phase III Results For Zemprocitinib In Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammat...

March 03, 2026 | News

Genentech Reports Phase III Success For Fenebrutinib With 51 Percent Relapse Reduction In Multiple Sclerosis

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relap...

March 03, 2026 | News

Blueprint Medicines Showcases Four Year AYVAKIT Data Reinforcing Durable Benefit In Indolent Systemic Mastocytosis

-- Real-world study of AYVAKIT highlights improvement across ISM symptoms -- -- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's ...

March 02, 2026 | Report

Gilead Reports Positive Phase 3 Data For Investigational Bictegravir And Lenacapavir Single Tablet Regimen

– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier ...

February 27, 2026 | News

Illumina Outlines NovaSeq X Roadmap With 40 Percent Output Increase And Q70 Quality Milestone

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolle...

February 26, 2026 | News

NEXT Life Sciences Advances Two Non Hormonal Male Contraceptives Into Phase II Trials

Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest...

February 23, 2026 | News

Stay Connected